In an adult with uncontrolled hypertension already on metoprolol (beta‑blocker) and olmesartan (angiotensin II receptor blocker), what additional medication can be added?

Add a Calcium Channel Blocker (CCB) or a Thiazide-Like Diuretic

For a patient on metoprolol (beta-blocker) and olmesartan (ARB) with uncontrolled hypertension, the preferred third agent is either a long-acting dihydropyridine calcium channel blocker (such as amlodipine) or a thiazide-like diuretic (chlorthalidone or indapamide). Both options are strongly supported by guideline evidence and provide complementary mechanisms of action to the existing regimen 1.

Preferred Third-Line Options

Option 1: Calcium Channel Blocker (CCB)

• Dihydropyridine CCBs (amlodipine, nifedipine) are the preferred choice
• The combination of ARB + CCB receives Grade A evidence when combined with an ACE inhibitor, and Grade B evidence when combined with an ARB 1
• This combination is particularly effective and well-tolerated 2, 3
• Avoid non-dihydropyridine CCBs (diltiazem, verapamil) with metoprolol due to risk of excessive bradycardia and heart block 1

Option 2: Thiazide-Like Diuretic

• Chlorthalidone or indapamide are preferred over hydrochlorothiazide (HCTZ) for superior cardiovascular protection 4
• Thiazide diuretics combined with ARBs receive Grade B evidence 1
• The 2020 ISH guidelines specifically recommend adding a thiazide-like diuretic as the third agent in non-Black patients already on ARB 5
• Monitor potassium levels to avoid hypokalemia 1

Clinical Decision Algorithm

Choose CCB if:

• Patient has peripheral edema concerns (CCB + ARB may reduce CCB-induced edema)
• Patient has concurrent angina
• Patient is Black (CCBs are particularly effective in this population) 6

Choose Thiazide-Like Diuretic if:

• Patient has volume overload or heart failure
• Cost is a significant concern (generally less expensive)
• Patient has osteoporosis (thiazides reduce calcium excretion)

Important Caveats

Beta-Blocker Considerations

• Metoprolol is not recommended as first-line therapy in patients ≥60 years old 1, though it may be appropriate if the patient has compelling indications (coronary artery disease, heart failure, post-MI)
• If the patient is ≥60 years without compelling indications, consider replacing metoprolol with a CCB or thiazide rather than adding a third agent

Combination Therapy Evidence

The most robust evidence supports the triple combination of ARB + CCB + thiazide-like diuretic 6, 5. Multiple international guidelines (ISH 2020, Hypertension Canada 2018-2020) recommend this specific three-drug regimen for resistant hypertension.

Fourth-Line Options (If Still Uncontrolled)

If blood pressure remains uncontrolled on olmesartan + metoprolol + CCB + thiazide-like diuretic:

1. Spironolactone 25-50 mg daily is the preferred fourth agent with Grade A evidence for resistant hypertension 4

   • Requires eGFR ≥45 mL/min/1.73 m²
   • Monitor potassium closely (risk of hyperkalemia with ARB + spironolactone)
   • Contraindicated if baseline potassium >4.5 mmol/L

2. Alternative fourth-line agents if spironolactone not tolerated:

   • Amiloride (potassium-sparing, fewer antiandrogenic effects) 4
   • Doxazosin (alpha-blocker)
   • Eplerenone (selective mineralocorticoid receptor antagonist)

Practical Implementation

• Start with standard doses: Amlodipine 5 mg daily or chlorthalidone 12.5-25 mg daily
• Titrate to effect after 2-4 weeks if blood pressure remains uncontrolled
• Target BP <130/80 mmHg per most recent guidelines 5, 7
• Single-pill combinations improve adherence and should be used when available 7, 3, 8
• Reassess medication adherence and screen for secondary hypertension if uncontrolled on three agents 1, 4